Results 351 to 360 of about 1,025,722 (378)
Some of the next articles are maybe not open access.
Medical Clinics of North America, 2001
To provide the most effective care for this difficult patient population, it is helpful to remember that patients with schizophrenia have disease-intrinsic limitations that limit their ability to participate in their care. These limitations are symptoms of a disease and not volitional.
D C, Goff, S, Heckers, O, Freudenreich
openaire +2 more sources
To provide the most effective care for this difficult patient population, it is helpful to remember that patients with schizophrenia have disease-intrinsic limitations that limit their ability to participate in their care. These limitations are symptoms of a disease and not volitional.
D C, Goff, S, Heckers, O, Freudenreich
openaire +2 more sources
Aripiprazole for schizophrenia
Cochrane Database of Systematic Reviews, 2003Treatment of people with schizophrenia using older typical antipsychotic drugs such as haloperidol can be problematic. Many fail to respond to these older antipsychotics and more people experience disabling adverse effects. Aripiprazole is said to be one of a new generation of atypical antipsychotics with good antipsychotic properties and minimal ...
Hany George El-Sayeh, Carla Morganti
openaire +4 more sources
Alexithymia and Schizophrenias
Psychopathology, 1995The purpose of this study is to verify whether an increasing degree of alexithymia correlates with a prevalence of negative over positive symptoms. The framework of the research is phenomenologically oriented conception of the illness-coping vulnerability paradigm.
Giovanni, Stanghellini, RICCA, VALDO
openaire +5 more sources
The Lancet, 2009
Schizophrenia is still one of the most mysterious and costliest mental disorders in terms of human suffering and societal expenditure. Here, we focus on the key developments in biology, epidemiology, and pharmacology of schizophrenia and provide a syndromal framework in which these aspects can be understood together.
Jim, van Os, Shitij, Kapur
openaire +4 more sources
Schizophrenia is still one of the most mysterious and costliest mental disorders in terms of human suffering and societal expenditure. Here, we focus on the key developments in biology, epidemiology, and pharmacology of schizophrenia and provide a syndromal framework in which these aspects can be understood together.
Jim, van Os, Shitij, Kapur
openaire +4 more sources
Psychiatric Clinics of North America, 1993
The pharmacologic treatment of the schizophrenic patient has remained substantively unchanged during the last 35 years. It is evident that as our knowledge of neuropharmacology has grown--the notion of schizophrenia being merely caused by a hyperdopaminergic state may be too simplistic.
S R, Marder +3 more
openaire +2 more sources
The pharmacologic treatment of the schizophrenic patient has remained substantively unchanged during the last 35 years. It is evident that as our knowledge of neuropharmacology has grown--the notion of schizophrenia being merely caused by a hyperdopaminergic state may be too simplistic.
S R, Marder +3 more
openaire +2 more sources
2010
Abstract Schizophrenia is a severe mental illness marked by hallucinations, delusions, reduced social drive, apathy, and cognitive impairment. Schizophrenia tends to develop in early adulthood and has a major impact on all aspects of functioning, including work, school, social relationships, and self-care.
Kim T. Mueser, Stephanie Marcello Duva
openaire +1 more source
Abstract Schizophrenia is a severe mental illness marked by hallucinations, delusions, reduced social drive, apathy, and cognitive impairment. Schizophrenia tends to develop in early adulthood and has a major impact on all aspects of functioning, including work, school, social relationships, and self-care.
Kim T. Mueser, Stephanie Marcello Duva
openaire +1 more source
A diagnostic interview: the schedule for affective disorders and schizophrenia.
Archives of General Psychiatry, 1978J. Endicott, R. Spitzer
semanticscholar +1 more source
Implications of normal brain development for the pathogenesis of schizophrenia.
Archives of General Psychiatry, 1987D. Weinberger
semanticscholar +1 more source
What are the functional consequences of neurocognitive deficits in schizophrenia?
American Journal of Psychiatry, 1996Michael F. Green
semanticscholar +1 more source
Remission in schizophrenia: proposed criteria and rationale for consensus.
American Journal of Psychiatry, 2005N. Andreasen +5 more
semanticscholar +1 more source